Sanofi-Aventis forms targeted oncology partnership with Ascenta Therapeutics
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis has strengthened its commitment to the busy field of targeted oncology therapies by signing an exclusive global collaboration and licensing agreement with Ascenta Therapeutics, a US biopharmaceutical company focused on orally active small-molecule drugs that restore apoptosis or programmed cell death.